Name: John Rhel T.

Denque Date: 05/16/18

Program: BSMT/BMLS
Course: Immunology and Serology
Tumor Marker Tissue Source Tumor Type Use
CA 125 Coelemic Ovarian  To help in
epithelium cystadenocarcinoma diagnosis,
Endometrial carcinoma assessment of
response to
treatment, and
evaluation of
recurrence
Alpha- Fetal liver  Hepatocarcinoma  To help diagnose
Fetoprotein Yolk sac  Endodermal sinus liver cancer and
tumors follow response to
 Non-seminomatous treatment; to assess
germ cell cancer stage, prognosis, and
 Teratocarcinoma of response to
testis or ovarian treatment of germ
 Mediastinum & cell tumors
sacrococcyx malignant
tumor
 Gastric Pancreatic
cancer w/ liver
metastasis
Thyroglobulin Thyroid gland  Thyroid cancer  To evaluate response
 Grave’s disease to treatment and
look for recurrence

CEA Normal fetal  Colon  Differentiate benign

endocrine tissue  Breast from malignant
 Lung ascites and pleural
 Liver effusion
 Pancreatic  Monitor tumor
progression
Huma Blood  Ovarian cancer  Monitor recurring
epididymis epithelial ovarian
Protein (HE4) cancer
 > 150. 1 pM
HER2/neu Oncogene encoded  Breast Cancer  Asses tumor
susceptibility to
therapy (e.i)
lapatinib &
transtuzumab
Prostate Prostatic epithelial  Prostate cancer  Other techniques:
Specific a. PSA velocity
Antigen (PSA) - Incremental
increase of
PSA/time
 b. PSA density
- Ratio of
serum PSA to
prostate
volume
c. Age-adjusted PSA
- Proportional

Prostatic ACP Prostate gland  Prostatic carcinoma  Monitoring and

Or hK2 and treatment
EPCA-2
CA 19-9 Blood  Main- pancreatic &  To assess whether
colorectal treatment is working
 Hepatobiliary
 Gastric
 Hepatocellular
 Breast
 Gastrointestinal cancer-
assoc antigen
CA 15- 3 MUC II gene  Breast cancer  Monitor after
Glandular mastectomy and
epithelial cells good measure for
tumor burden
 > 32 U/ml –
advanced breast
cancer & large tumor
burden
CA 27. 29 Human MUC I gene  Breast carcinoma  To assess whether
Breast  treatment is working,
Carcinoma- or disease has
Assoc Antigen recurred
EGFR Epithelial cells  Non-small cell lung  To help determine
cancer treatment and
prognosis

B-hCG  Choriocarcinoma To assess stage,

and germ cell prognosis, and response
tumors to treatment
 Oat cell carcinoma of
the lung

Lactate Blood Germ cell tumors, To assess stage,

dehydrogenase lymphoma, leukemia, prognosis, and response
melanoma, and to treatment
neuroblastoma
Name: John Rhel T. Denque
Date: 05/16/18

Generic name Antigen Target Treatment Application

Alemtuzumab CD52 Chronic lymphocytic

leukemia

Bevacizumab Vascular endothelial Prevention of vascularity in

growth factor tumor
antiangiogenesis (e.g.,
colorectal
and non-small cell lung
cancers)

Cetuximab Epidermal growth Colorectal, head and neck

factor receptor cancers

Rituximab CD 20 on Non-Hodgkin’s lymphoma

B-lymphocytes

Trastuzumab HER2/neu Breast cancer